Bas Thijssen

606 citations
21 papers · 461 · h-index 12

Impact in

  • Oncology
    • Cancer Treatment and Pharmacology
    • Drug Transport and Resistance Mechanisms
    • Colorectal Cancer Treatments and Studies
    • Pancreatic and Hepatic Oncology Research
  • Pharmacology top 10%
    • Pharmacogenetics and Drug Metabolism
    • Antibiotics Pharmacokinetics and Efficacy

Papers in

  • Oncology 11
    • Colorectal Cancer Treatments and Studies 6
    • Cancer Treatment and Pharmacology 5
  • Molecular Biology 10
    • Cancer therapeutics and mechanisms 4
    • PI3K/AKT/mTOR signaling in cancer 4
Co-authors
Jos H. Beijnen (20 shared papers)Hilde Rosing (20 shared papers)Jan H.M. Schellens (13 shared papers)Alwin D. R. Huitema (13 shared papers)Robert S. Jansen (1 shared paper)Ron J. Keizer (1 shared paper)Liia D. Vainchtein (2 shared papers)Serena Marchetti (8 shared papers)
Journals
Journal of Chromatography B (3 papers)Journal of Clinical Oncology (2 papers)Journal of Pharmaceutical and Biomedical Analysis (2 papers)British Journal of Cancer (1 paper)Clinical Cancer Research (1 paper)
Partner nations
NetherlandsSwitzerlandGermany

In The Last Decade

Bas Thijssen

21 papers receiving 457 citations

Peers

Bas Thijssen
Comparison fields: 5 of 90
  • Oncology 205
  • Pharmacology 62
  • Pharmacology 55
  • Transplantation 8
  • Hematology 33
Replace M. O. Karlsson with:
M. O. Karlsson Sweden
Katryn N. Furuya United States
Christopher Matheny United States
Niels de Vries Netherlands
Jason M. Gow United States
Martin Czejka Austria
Jos H. Beijnen Netherlands
Sushma Thomas United States
Takeshi Kotake Japan
Shinji Kobuchi Japan
Bas Thijssen relative to M. O. Karlsson Sweden M. O. Karlsson's profile →
Citations per field
00.5×2×4×6×8×10×
M. O. Karlsson · 1×
Citations per year

Countries citing papers authored by Bas Thijssen

Since Specialization
Citations

This map shows the geographic impact of Bas Thijssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bas Thijssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bas Thijssen more than expected).

Fields of papers citing papers by Bas Thijssen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bas Thijssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bas Thijssen. The network helps show where Bas Thijssen may publish in the future.

Co-authors

The 25 scholars most cited alongside Bas Thijssen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bas Thijssen Line = papers co-authored together Bas Thijssen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
Pharmacology Research & Perspectives ·Ron J. Keizer, Robert S. Jansen, Hilde Rosing, Bas Thijssen, Jos H. Beijnen, Jan H.M. Schellens, Alwin D. R. Huitema
2015151
2
A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry
Journal of Chromatography B ·Jeroen J. M. A. Hendrikx, M. J. X. Hillebrand, Bas Thijssen, Hilde Rosing, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen
201141
3
A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry
Biomedical Chromatography ·Liia D. Vainchtein, Bas Thijssen, Ellen Stokvis, Hilde Rosing, Jan H.M. Schellens, Jos H. Beijnen
200539
4
Validated assay for the simultaneous determination of the anti‐cancer agent gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine in human plasma by high‐performance liquid chromatography with tandem mass spectrometry
Rapid Communications in Mass Spectrometry ·Liia D. Vainchtein, Hilde Rosing, Bas Thijssen, Jan H.M. Schellens, Jos H. Beijnen
200730
5
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
British Journal of Cancer ·Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Ferry A.L.M. Eskens, Sanne C.F.A. Huijberts, Filip De Vos, Martijn P. Lolkema, Lot A. Devriese, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H.M. Schellens
202027
6
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer
Cancer Chemotherapy and Pharmacology ·Sanne C.F.A. Huijberts, Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, Saskia Pulleman, Bas Thijssen, Hilde Rosing, Kim Monkhorst, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H.M. Schellens
202026
7
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer
The Oncologist ·Emilie M.J. van Brummelen, Sanne C.F.A. Huijberts, Carla M.L. van Herpen, Ingrid M.E. Desar, Frans L. Opdam, Robin M.J.M. van Geel, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H.M. Schellens
202024
8
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir
European Journal of Cancer ·Vincent A. de Weger, Frederik E. Stuurman, Jeroen J. M. A. Hendrikx, Johannes J. Moes, Emilia Sawicki, Alwin D. R. Huitema, Bastiaan Nuijen, Bas Thijssen, Hilde Rosing, Marianne Keessen, Marja Mergui‐Roelvink, Jos H. Beijnen, Jan H.M. Schellens, Serena Marchetti
201722
9
Development and Clinical Validation of an LC–MS/MS Method for The Quantification of Pazopanib in DBS
Bioanalysis ·Remy B. Verheijen, Sander Bins, Bas Thijssen, Hilde Rosing, Lianda Nan, Jan H.M. Schellens, Ron H.J. Mathijssen, Martijn P. Lolkema, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema
201517
10
A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir
Clinical Cancer Research ·Vincent A. de Weger, Frederik E. Stuurman, Stijn L.W. Koolen, Johannes J. Moes, Jeroen J. M. A. Hendrikx, Emilia Sawicki, Bas Thijssen, Marianne Keessen, Hilde Rosing, Marja Mergui‐Roelvink, Alwin D. R. Huitema, Bastiaan Nuijen, Jos H. Beijnen, Jan H.M. Schellens, Serena Marchetti
201916
11
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients
Clinical Pharmacokinetics ·(unknown), Stefanie L. Groenland, Ruben A.G. van Eerden, Remy B. Verheijen, Niels de Vries, Bas Thijssen, Hilde Rosing, Jos H. Beijnen, Stijn L.W. Koolen, Ron H.J. Mathijssen, Alwin D. R. Huitema, Neeltje Steeghs
202011
12
Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue
Journal of Pharmaceutical and Biomedical Analysis ·Ignace C. Roseboom, Bas Thijssen, Hilde Rosing, Fabiana Alves, Dinesh Mondal, Marcel B. M. Teunissen, Jos H. Beijnen, Thomas P. C. Dorlo
202111
13
Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors.
Journal of Clinical Oncology ·Serena Marchetti, Frederik E. Stuurman, Stijn L.W. Koolen, Johannes J. Moes, Jeroen J. M. A. Hendrikx, Bas Thijssen, Alwin D. R. Huitema, Bastiaan Nuijen, Hilde Rosing, Marianne Keessen, Emile E. Voest, Marja Mergui‐Roelvink, Jos H. Beijnen, Jan H.M. Schellens
201210
14
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
Cancer Reports ·Marit A. C. Vermunt, Debbie Robbrecht, Lot A. Devriese, Julie M. Janssen, Bas Thijssen, Marianne Keessen, Maarten van Eijk, Rob Kessels, Ferry A.L.M. Eskens, Jos H. Beijnen, Niven Mehra, Andries M. Bergman
20219
15
Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma
Journal of Pharmaceutical and Biomedical Analysis ·Ignace C. Roseboom, Bas Thijssen, Hilde Rosing, Jane Mbui, Jos H. Beijnen, Thomas P. C. Dorlo
20208
16
Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS
Therapeutic Drug Monitoring ·Remy B. Verheijen, Bas Thijssen, Hilde Rosing, Jan H.M. Schellens, Lianda Nan, Nikkie Venekamp, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema
20176
17
Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue
Journal of Chromatography B ·Ignace C. Roseboom, Bas Thijssen, Hilde Rosing, Fabiana Alves, Shyam Sundar, Jos H. Beijnen, Thomas P. C. Dorlo
20224
18
Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours
Drugs in R&D ·Marit A. C. Vermunt, Vincent A. de Weger, Julie M. Janssen, Marta López‐Yurda, Marianne Keessen, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, Serena Marchetti
20214
19
Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
Cancers ·Laura Molenaar‐Kuijsten, Milan van Meekeren, Remy B. Verheijen, Judith V.M.G. Bovée, Marta Fiocco, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Aisha Miah, Hans Gelderblom, Rick L. Haas, Neeltje Steeghs
20212
20
Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue
Journal of Chromatography B ·Ignace C. Roseboom, Bas Thijssen, Hilde Rosing, Fabiana Alves, Brima M. Younis, Ahmed Musa, Jos H. Beijnen, Thomas P. C. Dorlo
20222

About Bas Thijssen

Bas Thijssen is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Pharmacology and Public Health, Environmental and Occupational Health, having authored 21 papers that have together received 461 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers), Pharmacogenetics and Drug Metabolism (5 papers), Lung Cancer Treatments and Mutations (5 papers), Cancer therapeutics and mechanisms (4 papers), Research on Leishmaniasis Studies (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Renal cell carcinoma treatment (2 papers). The work is most often cited by research in Oncology (205 citations), Pharmacology (62 citations), Pharmacology (55 citations), Transplantation (8 citations) and Hematology (33 citations). Bas Thijssen has collaborated with scholars based in Netherlands, Switzerland and Germany. Frequent co-authors include Jos H. Beijnen, Hilde Rosing, Jan H.M. Schellens, Alwin D. R. Huitema, Robert S. Jansen, Ron J. Keizer, Liia D. Vainchtein, Serena Marchetti, Jeroen J. M. A. Hendrikx and Neeltje Steeghs. Their work appears in journals such as Journal of Chromatography B, Journal of Clinical Oncology, Journal of Pharmaceutical and Biomedical Analysis, British Journal of Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. O. KarlssonBreakdown of academic impact, for papers by Katryn N. FuruyaBreakdown of academic impact, for papers by Christopher MathenyBreakdown of academic impact, for papers by Niels de VriesBreakdown of academic impact, for papers by Jason M. GowBreakdown of academic impact, for papers by Martin CzejkaBreakdown of academic impact, for papers by Jos H. BeijnenBreakdown of academic impact, for papers by Sushma ThomasBreakdown of academic impact, for papers by Takeshi KotakeBreakdown of academic impact, for papers by Shinji Kobuchi